ASLAN Pharmaceuticals Stock to Reverse Split on Wednesday, July 3rd (NASDAQ:ASLN)

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN)’s stock is scheduled to reverse split on the morning of Wednesday, July 3rd. The 1-8 reverse split was announced on Wednesday, July 3rd. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, July 3rd.

ASLAN Pharmaceuticals Price Performance

NASDAQ:ASLN opened at $0.30 on Monday. ASLAN Pharmaceuticals has a 1-year low of $0.27 and a 1-year high of $3.89. The company has a 50-day moving average of $0.41 and a 200 day moving average of $0.53. The firm has a market cap of $4.91 million, a PE ratio of -0.11 and a beta of 1.44.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.61). Sell-side analysts anticipate that ASLAN Pharmaceuticals will post -2.55 EPS for the current fiscal year.

Analyst Ratings Changes

ASLN has been the topic of several recent research reports. Piper Sandler reaffirmed an “overweight” rating and set a $10.00 target price (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a research report on Wednesday, March 13th. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of ASLAN Pharmaceuticals in a research note on Friday, May 3rd.

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases.